These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2859278)

  • 21. Subjective well-being and quality of life under atypical antipsychotic treatment.
    Karow A; Naber D
    Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
    Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia.
    Hofer A; Rettenbacher MA; Edlinger M; Kemmler G; Widschwendter CG; Fleischhacker WW
    Acta Psychiatr Scand; 2007 Nov; 116(5):354-61. PubMed ID: 17868428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
    Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
    Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving patient outcomes in schizophrenia: achieving remission.
    Nasrallah HA; Lasser R
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):57-61. PubMed ID: 17046987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancing medication use in schizophrenic patients.
    Diamond RJ
    J Clin Psychiatry; 1983 Jun; 44(6 Pt 2):7-14. PubMed ID: 6133855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia.
    Kim JH; Kim SY; Ahn YM; Kim YS
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):301-5. PubMed ID: 16309807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
    Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
    Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
    Hornung WP; Schonauer K; Feldmann R; Mönking HS
    Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
    Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
    Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study.
    Adrianzén C; Arango-Dávila C; Araujo DM; Ruíz I; Walton RJ; Dossenbach M; Karagianis J
    Hum Psychopharmacol; 2010 Aug; 25(6):439-47. PubMed ID: 20737517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.